MoonLake Immunotherapeutics

MLTX

Held by 2 specialist biotech funds

Share on X

Fund Holdings

Rock Springs Capital BVF Partners

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Rock Springs CapitalNEWFeb 17, 2026

Shares: 61,700Value: $813K

# Signal Note: Rock Springs Capital initiates MoonLake Immunotherapeutics (MLTX) Rock Springs' $813K entry into MLTX likely reflects conviction in the company's clinical pipeline, potentially including ML001 (being developed for inflammatory conditions) or upcoming data readouts that could de-risk valuation. As a healthcare-focused long/short specialist, Rock Springs' initiation suggests they see asymmetric risk/reward, though the small position size ($813K) indicates either early conviction or sizing appropriate to a micro-cap biotech with execution risk. Monitor for upcoming Phase 2 data or partnership announcements that could validate the thesis.

BVF PartnersNEW

More MLTX Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

OLMA2 funds MIRM2 funds CMPS2 funds GPCR2 funds RVMD2 funds KYMR2 funds MLYS1 fund NBIX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: BVF Partners Initiates $260M Position in MoonLake Immunotherapeutics (MLTX) Lampert's concentrated biotech fund establishing a significant 19.7M share stake signals conviction in MoonLake's lead candidate ML-002, a potential first-in-class CD19/CD20 bispecific for B-cell malignancies currently in clinical development. The ~$260M position size (at current valuation) represents meaningful capital deployment by a manager known for deep due diligence on clinical-stage molecules, likely reflecting confidence in upcoming trial readouts or commercial viability versus existing CAR-T/standard monotherapy options. Key near-term catalysts include clinical data presentations and progression milestones over the next 12-24 months.